Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezvilutamide plus ADT in Chinese prostate cancer patients (real-world safety study)
ChiCTR2400082040Phase 4Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rezvilutamide in prostate cancer (PCa), sponsored by Chinese PLA General Hospital. Primary endpoint: Safety. Started Mar 2024; status: recruiting.
02
Drugs
rezvilutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ChiCTR2400082040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082040.